Medicin og biovidenskab
Respiratory Syncytial Viruses
100%
Coronavirus
53%
Denmark
49%
Hospitalization
37%
Cost-Benefit Analysis
36%
Immunization
35%
Comorbidity
33%
Monoclonal Antibodies
31%
Respiratory Tract Infections
29%
Cohort Studies
28%
Mothers
27%
Intensive Care Units
17%
Population
16%
International Classification of Diseases
14%
Urea
13%
Child
13%
D-lactate dehydrogenase
12%
C-Reactive Protein
12%
Age Groups
11%
Creatinine
11%
Incidence
11%
Mortality
10%
Demography
9%
Severe Acute Respiratory Syndrome
9%
Registries
8%
Lymphopenia
8%
Health
8%
fibrin fragment D
8%
Netherlands
7%
Ferritins
7%
Costs and Cost Analysis
7%
L-Lactate Dehydrogenase
7%
Survival Analysis
6%
Thrombocytopenia
6%
Bronchiolitis
6%
Bronchitis
6%
Public Policy
5%
Delivery of Health Care
5%
Neutrophils
5%
Emergencies
5%
Administrative Personnel
5%
Health Policy
5%
Cross Infection
5%
Infections
5%
Multivariate Analysis
5%
Landbrug og biologi
Respiratory syncytial virus
63%
cost effectiveness
45%
immunization
41%
monoclonal antibodies
37%
willingness to pay
14%
Netherlands
7%
quality-adjusted life year
6%
Italy
6%
Samfundsvidenskab
infant
35%
willingness to pay
27%
costs
23%
scenario
20%
evaluation
19%
hospitalization
15%
Netherlands
11%
Perfect information
11%
life years
9%
leisure time
8%
Denmark
6%
Finland
6%
Italy
5%
health care
5%
